Tier 2 — strong

Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype

Sarah Egert, Christine Boesch-Saadatmandi, Siegfried Wolffram, Gerald Rimbach, Manfred J Müller
The Journal of nutrition 2010 140(2):278

Bibliography

PubMed
PMID 20032478
DOI
10.3945/jn.109.117655
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRetrospective APOE subgroup analysis of a randomized double-blind crossover trial
ModelHuman intervention research
Sample93 adults with overweight or obesity and metabolic-syndrome traits
InterventionQuercetin 150 mg/day or placebo
Duration6 weeks per period; 5-week washout
EndpointsBlood pressure; Lipid measurements

What the study showed, in plain terms

Published in 2010, this source examined cardiovascular and metabolic health. Design: Retrospective APOE subgroup analysis of a randomized double-blind crossover trial. Sample/model: 93 adults with overweight or obesity and metabolic-syndrome traits. The exposure or intervention was Quercetin 150 mg/day or placebo. Follow-up or treatment period: 6 weeks per period; 5-week washout.

Pressure and lipid responses differed by genotype; APOE4 carriers had reductions in HDL and apoA1 and an increased LDL-to-HDL ratio.

Retrospective small genotype subgroups and multiple outcomes. This is a secondary analysis of an existing intervention, not an independent trial or basis for personalized prescribing.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Pressure and lipid responses differed by genotype; APOE4 carriers had reductions in HDL and apoA1 and an increased LDL-to-HDL ratio.
  • The recorded outcome domains were Blood pressure; Lipid measurements.
  • The result applies to the tested exposure: Quercetin 150 mg/day or placebo; 6 weeks per period; 5-week washout.

What this study can and cannot tell us

  • Retrospective small genotype subgroups and multiple outcomes. This is a secondary analysis of an existing intervention, not an independent trial or basis for personalized prescribing.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study
Sarah Egert et al. · The British journal of nutrition · 2009
Tier 2
Effect of quercetin on paraoxonase 2 levels in RAW264.7 macrophages and in human monocytes--role of quercetin metabolism
Christine Boesch-Saadatmandi et al. · International journal of molecular sciences · 2009
Tier 2
Quercetin supplementation and its effect on human monocyte gene expression profiles in vivo
Inka Boomgaarden et al. · The British journal of nutrition · 2010
Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology